Bioanalytical Testing Services Market Size
| Study Period | 2018 - 2028 |
| Market Size (2023) | USD 3.60 Billion |
| Market Size (2028) | USD 5.59 Billion |
| CAGR (2023 - 2028) | 9.19 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bioanalytical Testing Services Market Analysis
The Bioanalytical Testing Services Market size is expected to grow from USD 3.60 billion in 2023 to USD 5.59 billion by 2028, at a CAGR of 9.19% during the forecast period (2023-2028).
Bioanalytical technologies have played a critical role in mitigating the COVID-19 pandemic and will continue to be foundational in the prevention of the subsequent waves of this pandemic, along with future infectious disease outbreaks. Companies, such as SGS, offer a full range of bioanalytical services for both small molecules and biologics, including mass spectrometry, immunoassays, and cell-based assays. In November 2020, SGS, the world's leading inspection, verification, testing, and certification company, invested in its Biosafety Center of Excellence in Glasgow, boosting its capacity to support scientists and manufacturers in the development of effective vaccines, cell and gene therapies, and other biological medicines.
The major factor contributing to the growth of the market studied is the increased necessity for specific types of tests in R&D activities and the increasing trend of outsourcing laboratory testing services. Due to the increasing trend of outsourcing laboratory testing services, companies are expanding their market share by offering various types of services and solutions. Additionally, major players are focusing on different strategies, such as mergers, acquisitions, and other developments. For instance, in August 2021, Eurofins Scientific signed an agreement with Noritsu Koki Co. Ltd to acquire GeneTech Inc., a leading Japanese player in genetic analysis, to expand Eurofins' testing portfolio in Japan. The bioanalytical testing service plays an important role; hence, the market is anticipated to grow significantly.
The rise in demand for bioanalytical testing services can also be due to the growing prevalence of infectious diseases, HIV, etc. Additionally, rising government initiatives to control the outbreaks of infectious diseases such as COVID-19 is expected to provide more opportunities, which is expected to contribute to the growth of the market studied.
Bioanalytical Testing Services Market Trends
This section covers the major market trends shaping the Bioanalytical Testing Services Market according to our research experts:
Small Molecule Sub-segment Expected to Show Better Growth in the Bioanalytical Testing Services Market
The small molecule testing services sub-segment is anticipated to witness growth due to its pivotal role in developing generic versions of branded drugs. Bioanalytical testing plays a significant role in proving the efficiency to simulate generic drug release profiles with that of branded drugs, resulting in the growth of the segment.
On the other hand, the large molecule segment is expected to witness lucrative growth during the forecast period. Bioanalytical testing of large molecules is one of the most challenging tasks for the biopharmaceutical sector. Hence, various techniques are used, such as Maldi-TOF-MS, Ligand Binding Assays, size exclusion affinity chromatography, etc. Bioanalytical testing of large molecules is generally conducted in well-established R&D labs by the biopharmaceutical sector, followed by other Phase II studies, while long-term toxicity studies are mostly outsourced. Hence, outsourcing bioanalytical testing of these molecules is likely to be the prevailing trend over the forecast period.
Owing to the COVID-19 pandemic, many biotech and pharmaceutical firms have been focusing on effective and rapid technologies for the fast diagnosis of COVID-19 and to develop vaccines/therapeutics that can help mitigate the spread by ensuring the appropriateness of care across all healthcare settings and achieving high-quality outcomes, which are further driving demand for the bioanalytical testing services globally. For instance, in July 2020, CIRION BioPharma Research Inc., a US-based GLP-certified contract research laboratory, announced that the company is expanding its bioanalytical services by increasing its existing laboratory facilities to support drug and vaccine developments related to COVID-19. Thus, the small molecule sub-segment is expected to contribute significantly over the forecast period due to the abovementioned factors.
To understand key trends, Download Sample Report
North America Dominates the Market and its Dominance Expected to Continue in the Forecast Period
North America is expected to dominate the bioanalytical testing services market, and this trend is expected to continue over the forecast period. This can be majorly attributed to the growing demand for bioanalytical services with a high volume of ongoing research activities and clinical trials, which is expected to fuel the market growth in the region.
In North America, the US holds the largest market share due to the increased patient pool of various chronic diseases and increased adoption of peptides and other large molecule therapeutics as an alternative to small molecules that have more side effects. According to the Centers for Disease Control and Prevention, around USD 3.5 trillion is spent on chronic diseases in the US. Therefore, companies have been taking initiatives to meet the high demand, which is expected to fuel the market studied.
Moreover, according to the International Diabetes Federation, in 2020, about 48 million adults in North America were living with diabetes, and the trend is expected to continue, resulting in higher demand for bioanalysis of novel therapeutics to stop the growing diabetes patient pool. Thus, the rising demand for bioanalytical services, the large number of ongoing clinical trials, and huge investments by many major pharmaceutical companies are the key factors driving the growth of the market studied in the country.
To understand geography trends, Download Sample Report
Bioanalytical Testing Services Industry Overview
The bioanalytical testing services market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by offering various types of services, launching new methods for assay validation, while others are offering laboratory solutions. Some companies currently dominating the market are SGS SA, ICON PLC, Laboratory Corporation of America Holdings, Syneos Health Inc., Charles River Laboratories Inc., etc.
Bioanalytical Testing Services Market Leaders
Syneos Health Inc
Charles River Laboratories Inc
Laboratory Corporation of America Holdings
ICON Plc
SGS SA
*Disclaimer: Major Players sorted in no particular order
Bioanalytical Testing Services Market News
· In November 2021, Labcorp launched a new bioanalytical lab facility in Singapore, which is an expansion of its central laboratory services and will help expand the capabilities of Singapore's biomedical ecosystem.
· In February 2021, Nexelis acquired GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory for expanding its bioanalytical capabilities.
Bioanalytical Testing Services Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Necessity of Specific Types of Tests in R&D Activities
4.2.2 Increased Trend of Outsourcing Laboratory Testing Services
4.3 Market Restraints
4.3.1 Complex Regulatory Framework for Maintaining Laboratories
4.3.2 Challenges in the Development of Proper Analytical Techniques
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Molecule Type
5.1.1 Small Molecules
5.1.2 Large Molecules
5.2 By Test Type
5.2.1 Bioavailability and Bioequivalence Studies
5.2.2 Pharmacokinetics
5.2.3 Pharmacodynamics
5.2.4 Other Test Types
5.3 Geography
5.3.1 North America
5.3.1.1 US
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 UK
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pharmaceutical Product Development LLC
6.1.2 ICON PLC
6.1.3 Laboratory Corporation of America Holdings
6.1.4 Charles River Laboratories International Inc.
6.1.5 Syneos Health
6.1.6 SGS SA
6.1.7 Toxikon Corporation
6.1.8 Intertek Group PLC
6.1.9 Wuxi Apptec Co. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Bioanalytical Testing Services Industry Segmentation
Bioanalysis involves quantitative measurement of xenobiotics, like small molecule drugs and their metabolites and biological molecules. Bioanalytical testing services are used in the development and validation of robust bioanalytical methods in body fluids and tissue specimens. These tests are used to support pre-clinical and Phase I through Phase IV clinical trials.
The bioanalytical testing services market is segmented by molecule type (small molecule and large molecule), by test type (bioavailability and bioequivalence studies, pharmacokinetics, pharmacodynamics, and other test types), and by geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Molecule Type | |
| Small Molecules | |
| Large Molecules |
| By Test Type | |
| Bioavailability and Bioequivalence Studies | |
| Pharmacokinetics | |
| Pharmacodynamics | |
| Other Test Types |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Bioanalytical Testing Services Market Research FAQs
How big is the Bioanalytical Testing Services Market?
The Bioanalytical Testing Services Market size is expected to reach USD 3,598.49 million in 2023 and grow at a CAGR of 9.19% to reach USD 5,585.14 million by 2028.
What is the current Bioanalytical Testing Services Market size?
In 2023, the Bioanalytical Testing Services Market size is expected to reach USD 3,598.49 million.
Who are the key players in Bioanalytical Testing Services Market?
Syneos Health Inc, Charles River Laboratories Inc, Laboratory Corporation of America Holdings, ICON Plc and SGS SA are the major companies operating in the Bioanalytical Testing Services Market.
Which is the fastest growing region in Bioanalytical Testing Services Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2023-2028).
Which region has the biggest share in Bioanalytical Testing Services Market?
In 2023, the North America accounts for the largest market share in the Bioanalytical Testing Services Market.
Bioanalytical Testing Services Industry Report
Statistics for the 2023 Bioanalytical Testing Services market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Bioanalytical Testing Services analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Bioanalytical Testing Services Market Report Snapshots
